{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:08:32Z","timestamp":1785798512101,"version":"3.56.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,9,1]],"date-time":"2000-09-01T00:00:00Z","timestamp":967766400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2000,9]]},"DOI":"10.1053\/ajkd.2000.16193","type":"journal-article","created":{"date-parts":[[2008,3,20]],"date-time":"2008-03-20T21:11:45Z","timestamp":1206047505000},"page":"550-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Intermittent doxercalciferol (1\u03b1-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism"],"prefix":"10.1053","volume":"36","author":[{"given":"Jo\u00e3o M.","family":"Fraz\u00e3o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loganathan","family":"Elangovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hla M.","family":"Maung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell W.","family":"Chesney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio R.","family":"Acchiardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Bower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby J.","family":"Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector J.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith C.","family":"Norris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barton S.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Mazess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene M.","family":"Kyllo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura L.","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack W.","family":"Coburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ajkd.2000.16193_bib1","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1172\/JCI114229","article-title":"The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion","volume":"84","author":"Brown","year":"1989","journal-title":"J Clin Invest"},{"issue":"suppl 3","key":"10.1053\/ajkd.2000.16193_bib2","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1093\/ndt\/11.supp3.121","article-title":"Effect of 22-oxacalcitriol on hyperparathyroidism of dialysis patients: Results of a preliminary study","volume":"11","author":"Kurokawa","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2000.16193_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s007740050026","article-title":"Efficacy and safety of oral falecalcitriol in reducing parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"16","author":"Morii","year":"1998","journal-title":"J Bone Miner Metab"},{"key":"10.1053\/ajkd.2000.16193_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1053\/ajkd.1998.v32.pm9708607","article-title":"Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism","volume":"32","author":"Akiba","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib5","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0272-6386(95)90455-7","article-title":"A new analog of calcitriol, 19-nor-1,25(OH)2 D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia","volume":"25","author":"Slatopolsky","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib6","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-\u03b1-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1053\/ajkd.2000.16193_bib7","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1093\/ndt\/11.supp3.153","article-title":"1\u03b1-Hydroxy-vitamin D2 : A new look at an \u2018old\u2019 compound","volume":"11","author":"Coburn","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2000.16193_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1\u03b1-hydroxyvitaminD2 in hemodialysis patients with moderates to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib9","first-page":"583","article-title":"Efficacy and safety of intermittent oral 1\u03b1 (OH)-vitamin D2 in suppressing 2o hyperparathyroidism in hemodialysis patients","volume":"26","author":"Frazao","year":"1997","journal-title":"Dial Transplant"},{"key":"10.1053\/ajkd.2000.16193_bib10","first-page":"145","article-title":"Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia","volume":"75","author":"Quarles","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/ajkd.2000.16193_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/ki.1993.64","article-title":"The spectrum of bone disease in end-stage renal failure\u2014An evolving disorder","volume":"43","author":"Sherrard","year":"1993","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib12","first-page":"2923","article-title":"Accumulation of a non (1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance of the interpretation of PTH values","volume":"81","author":"Brossard","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/ajkd.2000.16193_bib13","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/clinchem\/44.4.805","article-title":"A non-(1-84) circulating parathyroid hormone (PTH) fragment interferes significantly with intact PTH commercial assay measurement in uremic samples","volume":"44","author":"Lepage","year":"1998","journal-title":"Clin Chem"},{"key":"10.1053\/ajkd.2000.16193_bib14","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1093\/clinchem\/32.11.2060","article-title":"Assay of circulating 1,25-dihydroxyvitamin D involving a novel single-cartridge extraction and purification procedure","volume":"32","author":"Hollis","year":"1986","journal-title":"Clin Chem"},{"key":"10.1053\/ajkd.2000.16193_bib15","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/bi00454a035","article-title":"1-Alpha-hydroxylation of 24-hydroxyvitamin D2 represents a minor physiological pathway for the activation of vitamin D2 in mammals","volume":"29","author":"Horst","year":"1990","journal-title":"Biochemistry"},{"key":"10.1053\/ajkd.2000.16193_bib16","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1126\/science.157.3791.943","article-title":"Vitamin D2 and vitamin D3 in New World primates: Influence on calcium absorptions","volume":"158","author":"Hunt","year":"1967","journal-title":"Science"},{"key":"10.1053\/ajkd.2000.16193_bib17","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/ajcn\/22.3.358","article-title":"Hypervitaminosis D in the New World monkeys","volume":"22","author":"Hunt","year":"1969","journal-title":"Am J Clin Nutr"},{"key":"10.1053\/ajkd.2000.16193_bib18","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1093\/jn\/114.11.2043","article-title":"Antirachitic activity of 1\u03b1-hydroxyergocalciferol and 1\u03b1-hydroxycholecalciferol in rats","volume":"114","author":"Sj\u00f6den","year":"1984","journal-title":"J Nutr"},{"key":"10.1053\/ajkd.2000.16193_bib19","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","article-title":"1\u03b1-Hydroxyvitamin D2 is less toxic than 1\u03b1-hydroxyvitamin D3 in the rat","volume":"178","author":"Sj\u00f6den","year":"1985","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1053\/ajkd.2000.16193_bib20","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF02576679","article-title":"Effects of vitamin D2 analogs on calcium metabolism in vitamin D-deficient rats and in MC3T3 osteoblastic cells","volume":"191","author":"Sato","year":"1991","journal-title":"Res Exp Med"},{"key":"10.1053\/ajkd.2000.16193_bib21","first-page":"2156","article-title":"Unique 24-hydroxylated metabolites represent a significant pathway of metabolism of vitamin D2 in humans: 24-Hydroxyvitamin D2 and 1,24-dihydroxyvitamin D2 detectable in human serum","volume":"83","author":"Mawer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/ajkd.2000.16193_bib22","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1042\/bj3100233","article-title":"The 1\u03b1,24(S)-dihydroxy vitamin D2 : A biologically active product of 1\u03b1-OH-D2 made in the human hepatoma, Hep 3B","volume":"310","author":"Strugnell","year":"1995","journal-title":"Biochem J"},{"issue":"suppl 29","key":"10.1053\/ajkd.2000.16193_bib23","first-page":"S54","article-title":"Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy","volume":"38","author":"Coburn","year":"1990","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib24","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0272-6386(12)80831-6","article-title":"Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol","volume":"19","author":"Sprague","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib25","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/0272-6386(95)90454-9","article-title":"The importance of dosing intravenous calcitriol in dialysis patients with severe hyperparathyroidism","volume":"26","author":"Llach","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib26","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1172\/JCI116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1053\/ajkd.2000.16193_bib27","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/0140-6736(91)91429-X","article-title":"Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism?","volume":"337","author":"Klaus","year":"1991","journal-title":"Lancet"},{"key":"10.1053\/ajkd.2000.16193_bib28","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI111639","article-title":"Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients","volume":"74","author":"Slatopolsky","year":"1984","journal-title":"J Clin Invest"},{"key":"10.1053\/ajkd.2000.16193_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM199008093230617","article-title":"Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis","volume":"323","author":"Fukagawa","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2000.16193_bib30","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/ki.1994.375","article-title":"Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol","volume":"46","author":"Cannella","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib31","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/ki.1994.223","article-title":"Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD","volume":"45","author":"Quarles","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib32","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ki.1989.89","article-title":"1,25(OH)2 Vitamin D3 inhibits parathyroid cell proliferation in experimental uremia","volume":"35","author":"Szabo","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0272-6386(97)90571-0","article-title":"A new analog of 1,25(OH)2 D3, 19-nor-1,25(OH)2 D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content","volume":"30","author":"Takahashi","year":"1997","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib34","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/ajkd.2000.16193_bib35","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/ndt\/14.9.2178","article-title":"Association of hyperphosphatemia with haemodynamic disturbances in end-stage renal disease","volume":"14","author":"Marchais","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/ajkd.2000.16193_bib36","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1210\/jcem-73-3-516","article-title":"Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients","volume":"73","author":"Solal-Cohen","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/ajkd.2000.16193_bib37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1056\/NEJM198908033210502","article-title":"Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure","volume":"321","author":"Andress","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2000.16193_bib38","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","article-title":"Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy","volume":"46","author":"Goodman","year":"1994","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib39","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","article-title":"Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD","volume":"53","author":"Kuizon","year":"1998","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib40","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJM199803193381201","article-title":"Hypovitaminosis D in medical inpatients","volume":"338","author":"Thomas","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/ajkd.2000.16193_bib41","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1046\/j.1523-1755.1999.00480.x","article-title":"Is low plasma 25(OH) vitamin D a major risk factor for hyperparathyroidism and Looser\u2019s zones independent of calcitriol","volume":"55","author":"Ghazali","year":"1999","journal-title":"Kidney Int"},{"key":"10.1053\/ajkd.2000.16193_bib42","first-page":"822","article-title":"Effect of chronic intravenous calcitriol on parathyroid function and set point of calcium in dialysis patients with refractory secondary hyperparathyroidism","volume":"7","author":"Malberti","year":"1992","journal-title":"Nephrol Dial Transplant"},{"issue":"suppl 41","key":"10.1053\/ajkd.2000.16193_bib43","first-page":"S121","article-title":"Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1\u03b1(OH) vitamin D3, oral CaCO3 and low dialysate calcium","volume":"43","author":"Moriniere","year":"1993","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638600346649?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638600346649?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:19:18Z","timestamp":1759454358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638600346649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,9]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,9]]}},"alternative-id":["S0272638600346649"],"URL":"https:\/\/doi.org\/10.1053\/ajkd.2000.16193","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2000,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intermittent doxercalciferol (1\u03b1-Hydroxyvitamin D2) therapy for secondary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/ajkd.2000.16193","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}